Agendia Aims To Reshape Breast Cancer Care With Predictive Genomic Tests

William Audeh, chief medical officer at Agendia, is optimistic about study results suggesting the company’s genomic test MammaPrint, designed to predict which women with early-stage HR+ breast cancer are at risk of recurrence, also can be used to determine those that would benefit from extended endocrine therapy.